140,000 stock options granted to Immuneering Corp (IMRX) chief business officer

Rhea-AI Filing Summary

Immuneering Corp reported that its Chief Business Officer, Harold Eugene Brakewood, received a stock option award covering 140,000 shares of Class A common stock on February 3, 2026. The option has an exercise price of $4.91 per share and is held directly.

The option vests in equal monthly installments over four years, beginning on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. After this grant, Brakewood beneficially owns 140,000 derivative securities linked to Immuneering’s Class A common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brakewood Harold Eugene

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	140,000	$0.00	--

Holdings After Transaction: Stock Option — 140,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brakewood Harold Eugene

(Last) (First) (Middle)

C/O IMMUNEERING CORPORATION

245 MAIN STREET, SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.91	02/03/2026		A		140,000		(1)	02/03/2036	Class A Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Harold E. Brakewood	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Immuneering Corp (IMRX) report for Harold Eugene Brakewood?

Immuneering Corp reported a stock option grant to Chief Business Officer Harold Eugene Brakewood. He received options covering 140,000 shares of Class A common stock on February 3, 2026, as a derivative security award rather than a sale or purchase of existing shares.

How many Immuneering Corp (IMRX) shares are covered by the new stock option grant?

The new stock option grant covers 140,000 shares of Immuneering Corp’s Class A common stock. These shares are underlying a derivative security that gives the officer the right to buy stock at a fixed exercise price if and when he chooses to exercise the option.

What is the exercise price and structure of Harold Brakewood’s Immuneering (IMRX) stock option?

The stock option has an exercise price of $4.91 per share. It is a derivative security linked to Class A common stock, allowing Brakewood to purchase up to 140,000 shares at that price once the option becomes vested and exercisable over time.

What is the vesting schedule for the Immuneering Corp (IMRX) stock option granted on February 3, 2026?

The option vests in equal monthly installments over four years. Vesting begins on February 1, 2026, and continues until the award is fully vested and exercisable on January 1, 2030, aligning the officer’s incentives with longer-term company performance.

Does the reported Form 4 for Immuneering Corp (IMRX) show a stock sale by the officer?

No, the Form 4 shows a stock option award coded as an acquisition (A), not a sale. Brakewood received 140,000 stock options with a $4.91 exercise price, increasing his derivative holdings rather than reducing an existing position in Immuneering’s common stock.

How many derivative securities does Harold Brakewood own in Immuneering Corp (IMRX) after this grant?

After the reported transaction, Harold Brakewood beneficially owns 140,000 derivative securities. These consist of the newly granted stock option tied to Immuneering’s Class A common stock, all held with direct ownership as shown in the insider filing details.